Global Neuroblastoma Drugs Market Growth (Status and Outlook) 2025-2031

September 2025 | 75 pages | ID: GA9A3B2DF35EN
LP Information

Abstracts

According to this study, the global Neuroblastoma Drugs market size will reach US$ million by 2031.

Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Neuroblastoma Drugs Industry Forecast” looks at past sales and reviews total world Neuroblastoma Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neuroblastoma Drugs sales for 2025 through 2031. With Neuroblastoma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroblastoma Drugs industry.

This Insight Report provides a comprehensive analysis of the global Neuroblastoma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Neuroblastoma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuroblastoma Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroblastoma Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroblastoma Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Chemotherapy
• Immunotherapy
• Others

Segmentation by Application:

• Hospitals
• Clinics
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Pfizer
• Teva Pharmaceutical
• Johnson & Johnson
• Bristol-Myers Squibb
• United Therapeutics

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Neuroblastoma Drugs Market Size (2020-2031)
  2.1.2 Neuroblastoma Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Neuroblastoma Drugs by Country/Region (2020, 2024 & 2031)
2.2 Neuroblastoma Drugs Segment by Type
  2.2.1 Chemotherapy
  2.2.2 Immunotherapy
  2.2.3 Others
2.3 Neuroblastoma Drugs Market Size by Type
  2.3.1 Neuroblastoma Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Neuroblastoma Drugs Market Size Market Share by Type (2020-2025)
2.4 Neuroblastoma Drugs Segment by Application
  2.4.1 Hospitals
  2.4.2 Clinics
  2.4.3 Others
2.5 Neuroblastoma Drugs Market Size by Application
  2.5.1 Neuroblastoma Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Neuroblastoma Drugs Market Size Market Share by Application (2020-2025)

3 NEUROBLASTOMA DRUGS MARKET SIZE BY PLAYER

3.1 Neuroblastoma Drugs Market Size Market Share by Player
  3.1.1 Global Neuroblastoma Drugs Revenue by Player (2020-2025)
  3.1.2 Global Neuroblastoma Drugs Revenue Market Share by Player (2020-2025)
3.2 Global Neuroblastoma Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 NEUROBLASTOMA DRUGS BY REGION

4.1 Neuroblastoma Drugs Market Size by Region (2020-2025)
4.2 Global Neuroblastoma Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neuroblastoma Drugs Market Size Growth (2020-2025)
4.4 APAC Neuroblastoma Drugs Market Size Growth (2020-2025)
4.5 Europe Neuroblastoma Drugs Market Size Growth (2020-2025)
4.6 Middle East & Africa Neuroblastoma Drugs Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Neuroblastoma Drugs Market Size by Country (2020-2025)
5.2 Americas Neuroblastoma Drugs Market Size by Type (2020-2025)
5.3 Americas Neuroblastoma Drugs Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Neuroblastoma Drugs Market Size by Region (2020-2025)
6.2 APAC Neuroblastoma Drugs Market Size by Type (2020-2025)
6.3 APAC Neuroblastoma Drugs Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Neuroblastoma Drugs Market Size by Country (2020-2025)
7.2 Europe Neuroblastoma Drugs Market Size by Type (2020-2025)
7.3 Europe Neuroblastoma Drugs Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neuroblastoma Drugs by Region (2020-2025)
8.2 Middle East & Africa Neuroblastoma Drugs Market Size by Type (2020-2025)
8.3 Middle East & Africa Neuroblastoma Drugs Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL NEUROBLASTOMA DRUGS MARKET FORECAST

10.1 Global Neuroblastoma Drugs Forecast by Region (2026-2031)
  10.1.1 Global Neuroblastoma Drugs Forecast by Region (2026-2031)
  10.1.2 Americas Neuroblastoma Drugs Forecast
  10.1.3 APAC Neuroblastoma Drugs Forecast
  10.1.4 Europe Neuroblastoma Drugs Forecast
  10.1.5 Middle East & Africa Neuroblastoma Drugs Forecast
10.2 Americas Neuroblastoma Drugs Forecast by Country (2026-2031)
  10.2.1 United States Market Neuroblastoma Drugs Forecast
  10.2.2 Canada Market Neuroblastoma Drugs Forecast
  10.2.3 Mexico Market Neuroblastoma Drugs Forecast
  10.2.4 Brazil Market Neuroblastoma Drugs Forecast
10.3 APAC Neuroblastoma Drugs Forecast by Region (2026-2031)
  10.3.1 China Neuroblastoma Drugs Market Forecast
  10.3.2 Japan Market Neuroblastoma Drugs Forecast
  10.3.3 Korea Market Neuroblastoma Drugs Forecast
  10.3.4 Southeast Asia Market Neuroblastoma Drugs Forecast
  10.3.5 India Market Neuroblastoma Drugs Forecast
  10.3.6 Australia Market Neuroblastoma Drugs Forecast
10.4 Europe Neuroblastoma Drugs Forecast by Country (2026-2031)
  10.4.1 Germany Market Neuroblastoma Drugs Forecast
  10.4.2 France Market Neuroblastoma Drugs Forecast
  10.4.3 UK Market Neuroblastoma Drugs Forecast
  10.4.4 Italy Market Neuroblastoma Drugs Forecast
  10.4.5 Russia Market Neuroblastoma Drugs Forecast
10.5 Middle East & Africa Neuroblastoma Drugs Forecast by Region (2026-2031)
  10.5.1 Egypt Market Neuroblastoma Drugs Forecast
  10.5.2 South Africa Market Neuroblastoma Drugs Forecast
  10.5.3 Israel Market Neuroblastoma Drugs Forecast
  10.5.4 Turkey Market Neuroblastoma Drugs Forecast
10.6 Global Neuroblastoma Drugs Forecast by Type (2026-2031)
10.7 Global Neuroblastoma Drugs Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Neuroblastoma Drugs Forecast

11 KEY PLAYERS ANALYSIS

11.1 Pfizer
  11.1.1 Pfizer Company Information
  11.1.2 Pfizer Neuroblastoma Drugs Product Offered
  11.1.3 Pfizer Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Pfizer Main Business Overview
  11.1.5 Pfizer Latest Developments
11.2 Teva Pharmaceutical
  11.2.1 Teva Pharmaceutical Company Information
  11.2.2 Teva Pharmaceutical Neuroblastoma Drugs Product Offered
  11.2.3 Teva Pharmaceutical Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Teva Pharmaceutical Main Business Overview
  11.2.5 Teva Pharmaceutical Latest Developments
11.3 Johnson & Johnson
  11.3.1 Johnson & Johnson Company Information
  11.3.2 Johnson & Johnson Neuroblastoma Drugs Product Offered
  11.3.3 Johnson & Johnson Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Johnson & Johnson Main Business Overview
  11.3.5 Johnson & Johnson Latest Developments
11.4 Bristol-Myers Squibb
  11.4.1 Bristol-Myers Squibb Company Information
  11.4.2 Bristol-Myers Squibb Neuroblastoma Drugs Product Offered
  11.4.3 Bristol-Myers Squibb Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Bristol-Myers Squibb Main Business Overview
  11.4.5 Bristol-Myers Squibb Latest Developments
11.5 United Therapeutics
  11.5.1 United Therapeutics Company Information
  11.5.2 United Therapeutics Neuroblastoma Drugs Product Offered
  11.5.3 United Therapeutics Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 United Therapeutics Main Business Overview
  11.5.5 United Therapeutics Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Neuroblastoma Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Neuroblastoma Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Immunotherapy
Table 5. Major Players of Others
Table 6. Neuroblastoma Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Neuroblastoma Drugs Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Neuroblastoma Drugs Market Size Market Share by Type (2020-2025)
Table 9. Neuroblastoma Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Neuroblastoma Drugs Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Neuroblastoma Drugs Market Size Market Share by Application (2020-2025)
Table 12. Global Neuroblastoma Drugs Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Neuroblastoma Drugs Revenue Market Share by Player (2020-2025)
Table 14. Neuroblastoma Drugs Key Players Head office and Products Offered
Table 15. Neuroblastoma Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Neuroblastoma Drugs Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Neuroblastoma Drugs Market Size Market Share by Region (2020-2025)
Table 20. Global Neuroblastoma Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Neuroblastoma Drugs Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Neuroblastoma Drugs Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Neuroblastoma Drugs Market Size Market Share by Country (2020-2025)
Table 24. Americas Neuroblastoma Drugs Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Neuroblastoma Drugs Market Size Market Share by Type (2020-2025)
Table 26. Americas Neuroblastoma Drugs Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Neuroblastoma Drugs Market Size Market Share by Application (2020-2025)
Table 28. APAC Neuroblastoma Drugs Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Neuroblastoma Drugs Market Size Market Share by Region (2020-2025)
Table 30. APAC Neuroblastoma Drugs Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Neuroblastoma Drugs Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Neuroblastoma Drugs Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Neuroblastoma Drugs Market Size Market Share by Country (2020-2025)
Table 34. Europe Neuroblastoma Drugs Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Neuroblastoma Drugs Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Neuroblastoma Drugs Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Neuroblastoma Drugs Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Neuroblastoma Drugs Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Neuroblastoma Drugs
Table 40. Key Market Challenges & Risks of Neuroblastoma Drugs
Table 41. Key Industry Trends of Neuroblastoma Drugs
Table 42. Global Neuroblastoma Drugs Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Neuroblastoma Drugs Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Neuroblastoma Drugs Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Neuroblastoma Drugs Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. Pfizer Details, Company Type, Neuroblastoma Drugs Area Served and Its Competitors
Table 47. Pfizer Neuroblastoma Drugs Product Offered
Table 48. Pfizer Neuroblastoma Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. Pfizer Main Business
Table 50. Pfizer Latest Developments
Table 51. Teva Pharmaceutical Details, Company Type, Neuroblastoma Drugs Area Served and Its Competitors
Table 52. Teva Pharmaceutical Neuroblastoma Drugs Product Offered
Table 53. Teva Pharmaceutical Neuroblastoma Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. Teva Pharmaceutical Main Business
Table 55. Teva Pharmaceutical Latest Developments
Table 56. Johnson & Johnson Details, Company Type, Neuroblastoma Drugs Area Served and Its Competitors
Table 57. Johnson & Johnson Neuroblastoma Drugs Product Offered
Table 58. Johnson & Johnson Neuroblastoma Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Johnson & Johnson Main Business
Table 60. Johnson & Johnson Latest Developments
Table 61. Bristol-Myers Squibb Details, Company Type, Neuroblastoma Drugs Area Served and Its Competitors
Table 62. Bristol-Myers Squibb Neuroblastoma Drugs Product Offered
Table 63. Bristol-Myers Squibb Neuroblastoma Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Bristol-Myers Squibb Main Business
Table 65. Bristol-Myers Squibb Latest Developments
Table 66. United Therapeutics Details, Company Type, Neuroblastoma Drugs Area Served and Its Competitors
Table 67. United Therapeutics Neuroblastoma Drugs Product Offered
Table 68. United Therapeutics Neuroblastoma Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. United Therapeutics Main Business
Table 70. United Therapeutics Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Neuroblastoma Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neuroblastoma Drugs Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Neuroblastoma Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Neuroblastoma Drugs Sales Market Share by Country/Region (2024)
Figure 8. Neuroblastoma Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Neuroblastoma Drugs Market Size Market Share by Type in 2024
Figure 10. Neuroblastoma Drugs in Hospitals
Figure 11. Global Neuroblastoma Drugs Market: Hospitals (2020-2025) & ($ millions)
Figure 12. Neuroblastoma Drugs in Clinics
Figure 13. Global Neuroblastoma Drugs Market: Clinics (2020-2025) & ($ millions)
Figure 14. Neuroblastoma Drugs in Others
Figure 15. Global Neuroblastoma Drugs Market: Others (2020-2025) & ($ millions)
Figure 16. Global Neuroblastoma Drugs Market Size Market Share by Application in 2024
Figure 17. Global Neuroblastoma Drugs Revenue Market Share by Player in 2024
Figure 18. Global Neuroblastoma Drugs Market Size Market Share by Region (2020-2025)
Figure 19. Americas Neuroblastoma Drugs Market Size 2020-2025 ($ millions)
Figure 20. APAC Neuroblastoma Drugs Market Size 2020-2025 ($ millions)
Figure 21. Europe Neuroblastoma Drugs Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Neuroblastoma Drugs Market Size 2020-2025 ($ millions)
Figure 23. Americas Neuroblastoma Drugs Value Market Share by Country in 2024
Figure 24. United States Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Neuroblastoma Drugs Market Size Market Share by Region in 2024
Figure 29. APAC Neuroblastoma Drugs Market Size Market Share by Type (2020-2025)
Figure 30. APAC Neuroblastoma Drugs Market Size Market Share by Application (2020-2025)
Figure 31. China Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 35. India Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Neuroblastoma Drugs Market Size Market Share by Country in 2024
Figure 38. Europe Neuroblastoma Drugs Market Size Market Share by Type (2020-2025)
Figure 39. Europe Neuroblastoma Drugs Market Size Market Share by Application (2020-2025)
Figure 40. Germany Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 41. France Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Neuroblastoma Drugs Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Neuroblastoma Drugs Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Neuroblastoma Drugs Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Neuroblastoma Drugs Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 54. APAC Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 55. Europe Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 57. United States Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 58. Canada Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 59. Mexico Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 60. Brazil Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 61. China Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 62. Japan Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 63. Korea Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 65. India Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 66. Australia Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 67. Germany Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 68. France Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 69. UK Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 70. Italy Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 71. Russia Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 72. Egypt Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 73. South Africa Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 74. Israel Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 75. Turkey Neuroblastoma Drugs Market Size 2026-2031 ($ millions)
Figure 76. Global Neuroblastoma Drugs Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Neuroblastoma Drugs Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Neuroblastoma Drugs Market Size 2026-2031 ($ millions)